Brought to you by 
Biogen gets license to REGENXBIO's AAV vectors
15 Aug 2017
Executive Summary
REGENXBIO Inc. licensed Biogen Inc. exclusive global rights, along with sublicensing rights, to adeno-associated virus serotype 8 (AAV8) or 9 (AAV9) vectors for use in developing gene therapies aimed at two rare genetic vision disorders.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biogen gets license to REGENXBIO's AAV vectors
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice